Schlumberger NV vs Zoetis Inc — how do they compare? Schlumberger NV trades at $57.07 (market cap $84.74B), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Schlumberger NV is far larger — about 2.8× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| SLB | ZTS | |
|---|---|---|
Market Cap | $84.74B | $30.40B |
Sector | Energy | Health |
52-Week High | $60.10 | $150.61 |
52-Week Low | $31.72 | $71.91 |
Enterprise Value | $93.47B | $37.96B |
Dividend Yield | 2.07% | 2.88% |
Signals from Pluang's Aura AI — not financial advice
SLB trades at $57.10, down 0.71% on the day, with strong analyst support (85% buy ratings) and a $63.50 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a strategic $3.4 billion acquisition of Kelvion to expand into data center cooling technology. Revenue remains stable at $35.7 billion (2025) with solid profitability metrics including 8.53% net margin and 13.37% ROE.
The outlook remains positive with diversification into high-growth data center markets, though risks include oil price volatility and execution challenges from recent acquisitions. Current valuation at 27.85 P/E appears reasonable given growth initiatives, supporting a constructive view for long-term investors despite near-term market fluctuations.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →